Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer (RIBOLARIS)

• ClinicalTrials.gov Identifier: NCT05296746
• Recruitment Status: Recruiting
• First Posted: March 25, 2022
• Last Update Posted: October 10, 2023
• Sponsor: SOLTI Breast Cancer Research Group
• Collaborators: Novartis; UNICANCER
• Information provided by (Responsible Party): SOLTI Breast Cancer Research Group

Study Description

Brief Summary:

This is an open-label, multicenter international trial in men and women with primary operable HR+/HER2-, ki67≥20%, grade 2 or 3 and stage II breast cancer to evaluate safety and long-term efficacy of a non-chemo treatment in patients biologically responders to neoadjuvant ribociclib and letrozole.

This study aims to evaluate whether chemotherapy could be avoided for initial high-risk clinicopathological breast cancer patients that are converted to low genomic risk assessed by Risk of Recurrence-low (ROR-low) at 6 months of letrozole - ribociclib neoadjuvant treatment by continuing with this treatment in adjuvant setting.

Condition or disease	Intervention/treatment	Phase
Breast Cancer Stage II	Drug: Ribociclib (neoadjuvant); Drug: Chemotherapy (adjuvant); Drug: Ribociclib (adjuvant)	Phase 2

Detailed Description:

All patients will receive letrozole plus ribociclib as neoadjuvant therapy. Treatment will consist of six 28-days cycles of daily letrozole (2.5mg; continuous) and ribociclib (600 mg/day; 3 weeks ON and 1 week OFF). In pre-menopausal and men patients, monthly LHRH agonists will be added to letrozole and ribociclib, beginning at least two weeks before starting letrozole and ribociclib.

After finalization of neoadjuvant treatment, patients will undergo surgery. Surgery samples of the residual tumor tissue (or tumor bed if pathological complete response [pCR] is achieved) will be collected regardless of whether they completed full neoadjuvant treatment.

This is not a randomized study; therefore, adjuvant treatment will be decided according to centrally assessed ROR and pathological stage after surgery. Patients are considered responders if they achieve a pCR or have ypN0 and ROR ≤ 30 or ypN1mi (cancer the lymph node is > 0.2 mm but < 2 mm) and ROR ≤ 20 or ypN1 and ROR ≤ 10. All patients with ypN0 and ROR > 30, ypN1mi and ROR > 20, ypN1 and ROR > 10 or ypN2-3 are considered non-responders. Patients who progress during neoadjuvant treatment with ribociclib will be considered non-responders.

If indicated, adjuvant radiotherapy will be performed after surgery in the responder group and after adjuvant chemotherapy in the non-responders group.

Patients considered as responders will continue on treatment after optimal recovery of surgery and radiotherapy if indicated. Treatment with ribociclib (400 mg/day; 3 weeks ON and 1 week OFF) in the adjuvant setting will be maintained for 30 months approximately corresponding to 33 cycles. Letrozole treatment duration must be of at least 5 years. Visits during ribociclib treatment will be scheduled every three cycles. At the end of ribociclib treatment, visits will be every 6 months until 5 years from last patient's surgery.

Patients considered as non-responders will be treated with standard chemotherapy regimens. Patients will continue treatment with ribociclib and letrozole after optimal recovery of adjuvant chemotherapy and radiotherapy if indicated. Treatment with ribociclib (400 mg/day; 3 weeks ON and 1 week OFF) in the adjuvant setting will be maintained for 30 months approximately corresponding to 33 cycles after adjuvant chemotherapy. Endocrine therapy treatment duration must be of at least 5 years. Visits during ribociclib treatment will be scheduled every three cycles. At the end of ribociclib treatment, visits will be every 6 months until 5 years from last patient's surgery.

During adjuvant treatment (both responders and non-responders), letrozole can be switched to another aromatase inhibirtor (AI). Tamoxifen is only permitted after the 30-day post ribociclib visit, according to investigator criteria. Maintaining suppression of ovarian function by luteinizing hormone releasing hormone (LHRH) agonists during adjuvant treatment is mandatory (if AI are taken)/ recommended (if tamoxifen is taken) in premenopausal and men patients unless there is unmanageable toxicity.

Adjuvant hormonal treatment of patients who progress during neoadjuvant Ribociclib will be at the investigator's discretion.

Blood samples for ctDNA will be collected at screening, C2D1, pre-surgery, post-surgery, and every 6 months during the adjuvant period. Blood samples will be also collected in case of recurrence.

The global end of the study is defined as the date when the last patient accomplishes 5 years of follow up after surgery. The total duration of the study is expected to be 32 months for enrollment, 3 years of adjuvant treatment (including 2.5 years of ribociclib treatment), and additional 2.5 years of follow-up.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 1100 participants
• Allocation: Non-Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Neoadjuvant and Adjuvant Ribociclib and Endocrine Therapy for Clinically High-risk Estrogen Receptor-positive (ER+) and HER2-negative (HER2-) Breast Cancer
• Actual Study Start Date: May 3, 2022
• Estimated Primary Completion Date: August 1, 2028
• Estimated Study Completion Date: July 1, 2030

Arms and Interventions

Arm	Intervention/treatment
Experimental: Responder (ROR-low); Ribociclib (400 mg/day; 3 weeks ON and 1 week OFF) in the adjuvant setting for 33 cycles. Letrozole or other aromatase inhibitor treatment duration must be of at least 5 years	Drug: Ribociclib (neoadjuvant); Ribociclib 600 mg/day + letrozole during neoadjuvant phase.; Other Name: Kisqali; Drug: Ribociclib (adjuvant); Ribociclib 400 mg/day + letrozole (or other aromatase inhibitor) during adjuvant phase.; Other Name: Kisqali
Non-responder (ROR-medium/high); Adjuvant chemotherapy. 3 regimens are permitted. Regimen 1: - Doxorubicin 60 mg/m2 IV day 1 (or Epirubicin 75-100 mg/m2) and Cyclophosphamide 600-830 mg/m2 day 1 every 14/21 days for 4 cycles, followed by Paclitaxel 80 mg/m2 every week for 12 weeks or Docetaxel 75-100 mg/m2 every 3 weeks for 12 weeks. Regimen 2: - Docetaxel 75-100 mg/m2 IV day 1 and Cyclophosphamide 600-830 mg/m2 day 1 every 21 days for 4-6 cycles. Regimen 3: - Paclitaxel 80 mg/m2 every week for 12 weeks or Docetaxel 75-100 mg/m2 every 3 weeks for 12 weeks followed by Doxorubicin 60 mg/m2 IV day 1 (or Epirubicin 75-100 mg/m2) and Cyclophosphamide 600-830 mg/m2 day 1 every 14/21 days for 4 cycles. Then, patients will receive ribociclib (400 mg/day; 3 weeks ON and 1 week OFF) in the adjuvant setting for 33 cycles. Letrozole or other aromatase inhibitor treatment duration must be of at least 5 years	Drug: Ribociclib (neoadjuvant); Ribociclib 600 mg/day + letrozole during neoadjuvant phase.; Other Name: Kisqali; Drug: Chemotherapy (adjuvant); Adjuvant chemotherapy. 3 regimens are permitted.; Drug: Ribociclib (adjuvant); Ribociclib 400 mg/day + letrozole (or other aromatase inhibitor) during adjuvant phase.; Other Name: Kisqali

Outcome Measures

Primary Outcome Measures :

1. Distant metastasis-free survival (DMFS) in the ROR-low cohort (responder cohort) [ Time Frame: Until recurrence (if it happens) for a maximum of 7.5 years of follow-up ]
   DMFS is defined as the time from date of surgery to date of first event of distant metastatic recurrence or death (any cause).

Secondary Outcome Measures :

1. Invasive disease-free survival (IDFS) in the ROR-low cohort (responder cohort) [ Time Frame: Until recurrence (if it happens) for a maximum of 7.5 years of follow-up ]
   iDFS is defined as the time from surgery until the date of the first occurrence of one of the following events: recurrence of ipsilateral invasive breast tumor, recurrence of ipsilateral locoregional invasive disease, a distant disease recurrence, contralateral invasive breast cancer, second primary or death from any cause.
2. Pathological complete response in breast and axillary lymph nodes (pCRBL) [ Time Frame: At surgery (after 6 months of neoadjuvant treatment) ]
   pCRBL after completion of study treatment, defined as the complete absence of invasive carcinoma in the breast and axillary lymph nodes on histological examination at the time of definitive surgery, irrespective of in situ carcinoma in the breast.
3. Residual Cancer Burden 0/1 (RCB0/1) [ Time Frame: At surgery (after 6 months of neoadjuvant treatment) ]
   RCB0/1 after neoadjuvant treatment, according to the MD Anderson Cancer Center procedures, as per local assessment.
4. Rate of ROR-low (at surgery) after neoadjuvant treatment. [ Time Frame: At surgery (after 6 months of neoadjuvant treatment) ]
   Rate of ROR-low (at surgery) after neoadjuvant treatment, according to Prosigna test.
5. Distant metastasis-free survival (DMFS) in the ROR-medium/high cohort (non-responder cohort) [ Time Frame: Until recurrence (if it happens) for a maximum of 7.5 years of follow-up ]
   DMFS is defined as the time from date of surgery to date of first event of distant metastatic recurrence or death (any cause).
6. Incidence, duration and severity of Adverse Events (AEs) [ Time Frame: From ICF signature until the end of treatment visit ]
   Incidence, duration and severity of Adverse Events (AEs) assessed by the National Cancer Instirute (NCI) Common Terminology for Classification of Adverse Events (CTCAE) version 4.03, including dose reductions, delays and treatment discontinuations.

Other Outcome Measures:

1. Correlation between DMFS and pCR [ Time Frame: Until recurrence (if it happens) for a maximum of 7.5 years of follow-up ]
   Correlation between DMFS and pCR in ROR-low cohort, in ROR-medium/high cohort, and in all patients
2. Correlation between DMFS and ROR score (as a continuous variable) [ Time Frame: Until recurrence (if it happens) for a maximum of 7.5 years of follow-up ]
   Correlation between DMFS and ROR score (as a continuous variable) in ROR-low cohort, in ROR-medium/high cohort, and in all patients.
3. Correlation between DMFS and RCB [ Time Frame: Until recurrence (if it happens) for a maximum of 7.5 years of follow-up ]
   Correlation between DMFS and RCB at surgery in ROR-low cohort, in ROR-medium/high cohort, and in all patients
4. Correlation between DMFS and PAM50 intrinsic breast cancer subtype at surgery [ Time Frame: Until recurrence (if it happens) for a maximum of 7.5 years of follow-up ]
   Correlation between DMFS and PAM50 intrinsic breast cancer subtype at surgery in ROR-low cohort, in ROR-medium/high cohort, and in all patients
5. Correlation between DMFS and PAM50 intrinsic breast cancer subtype at baseline [ Time Frame: Until recurrence (if it happens) for a maximum of 7.5 years of follow-up ]
   Correlation between DMFS and PAM50 intrinsic breast cancer subtype at baseline in ROR-low cohort, in ROR-medium/high cohort, and in all patients
6. To perform correlative studies based on ctDNA analysis. [ Time Frame: From ICF signature until recurrence ]
   • To evaluate the predictive value of early dynamic changes in ctDNA between baseline and after 1 cycle of ribociclib + letrozole.
   • Correlation of clinical benefit endpoints and specific baseline genomic alterations or patterns in ctDNA.
   • To explore the value of ctDNA to detect a later clinical recurrence during the adjuvant phase.
   • To explore alterations or patterns related to drug resistance.
7. To Evaluate plasma Thymidine Kinase 1 activity (TKa) over time as a proliferation blood marker and its association with clinical outcome. [ Time Frame: From ICF signature until recurrence ]
   To correlate TKa dynamics with DMFS, IDFS, pCR and RCB0/1.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Signed Informed Consent Form prior to any study-specific procedure. Patients must be willing and able to comply with the protocol for the duration of the study including scheduled visits, treatment plan, laboratory tests and other study procedures.

   Note: Candidate patients in France must be affiliated to a Social Security System (or equivalent)

2. Male (≥18 years old) or pre-menopausal women (≥40 years old) or post-menopausal women. Premenopausal/male patients will receive LHRH agonists 2 weeks before C1D1 and during treatment. Post-menopausal status is defined as:

   1. Age ≥60 years or
   2. Age <60 years and 12 months of amenorrhea plus follicle stimulating hormone (FSH) and plasma estradiol (E2) levels within post-menopausal range by local laboratory assessment or
   3. Prior bilateral oophorectomy (≥7 days prior to Day 1 of treatment).

3. Histologically confirmed invasive breast carcinoma, confirmed by the local pathologist, with all the following characteristics:

   1. Clinical stage II (Seventh Edition of the AJCC) which includes cT1cN1cM0, cT2cN0cM0, cT2cN1cM0 and cT3cN0cM0.
   2. ER-positive/HER2-negative according to the most recent ASCO/CAP guidelines assessed locally, tumor cells >10% ER staining, grade 2 or 3 breast cancer.
   3. Ki-67 index by local analysis of ≥20% on untreated tumor tissue and/or high genomic risk (defined by gene signature): Oncotype DX® RS ≥ 26, Mammaprint® = Risk of Recurrence High, Prosigna® ROR ≥ 60 or luminal B, or Endopredict® = Risk of Recurrence High.

   Note: Multifocal and multicentric tumors are permitted if they are considered clinical stage II according to Seventh Edition of the AJCC. Biopsy of all lesions is not necessary.

4. Breast cancer eligible for primary surgery.
5. Available pre-treatment FFPE core (tru-cut) biopsy evaluable for PAM50 or possibility to obtain one. Minimal sample requirements are to have at least 1 tumor cylinder with a minimal tissue surface of 4 mm2 tissue, containing at least 10% tumor cells and having enough tissue to do at least 2 cuts of 10 μm each (the quality of the sample must be approved centrally prior to inclusion).
6. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. Evaluation of ECOG is to be performed within 14 days prior to the date of enrolment.

7. Adequate hematological, renal and hepatic function, as follows:

   1. Absolute neutrophil count (ANC) ≥1.5 x 109/L
   2. Platelet count ≥100 x 109/L
   3. Hemoglobin ≥10 g/dL
   4. Alkaline phosphatase (AP) ≤2.5x upper limit of normal (ULN)
   5. Total bilirubin <ULN. Patients with known Gilbert syndrome may be enrolled with total bilirubin ≤3 x ULN or direct bilirubin ≤1.5 x ULN.
   6. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <2.5x ULN
   7. Serum creatinine ≤1.5 mg/dL or calculated creatinine clearance ≥60 mL/min (Cockcroft-Gault Equation)
   8. Potassium, total calcium (corrected for serum albumin), magnesium, and sodium within institutional normal limits or corrected to within normal limits with supplements before first dose of study medication.

   Male participants:

8. A male participant must agree to use a contraception as detailed in Appendix 1 of this protocol during the adjuvant chemotherapy period (only non-responder cohort) and for at least 21 days, corresponding to time needed to eliminate any study treatments plus an additional 120 days (a spermatogenesis cycle) after the last dose of chemotherapy and refrain from donating sperm during this period. After the end of trial treatment, patients should use effective contraception according to local guidelines.

   Female participants:

9. A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies (see Appendix 1):

   1. Not a woman of childbearing potential (WOCBP) as defined in Appendix 1 OR
   2. A WOCBP who agrees to follow the contraceptive guidance in Appendix 1 during the treatment period and for at least 21 days (corresponding to time needed to eliminate any study treatments) plus 30 days (a menstruation cycle) for study treatments with risk of genotoxicity after the last dose of study treatment. After the end of trial treatment, patients should use effective contraception according to local guidelines.

Exclusion Criteria:

1. Any prior treatment for primary invasive breast cancer. Letrozole or other drugs used during the preservation of ovarian function are permitted if administered after baseline biopsy.
2. Inoperable breast cancer.
3. Patients with Stage I, III or IV breast cancer are not eligible. Baseline staging to document absence of metastatic disease is not required, however is recommended as determined by institutional practice (in patients where there may be a reasonable suspicion of advanced disease e.g., large tumors, clinically positive axillary lymph nodes, signs and symptoms). If performed, reports of these examinations must be available. Examination type for staging, i.e. X-ray, sonography, bone scan, CT, MRI, and/or PET-CT, is at the discretion of the investigator.
4. Bilateral invasive breast cancer.
5. Patients who have undergone sentinel lymph node biopsy prior to study treatment.
6. Inability or unwillingness to swallow pills.
7. Malabsorption syndrome or other condition that would interfere with enteric absorption of study drugs.
8. Participation in a prior investigational study within 30 days prior to enrolment or within 5 half-lives of the investigational product, whichever is longer.
9. Patient with a Child-Pugh score B or C.

10. Patient has active cardiac disease or a history of cardiac dysfunction including any of the following:

    1. History of acute coronary syndromes (including myocardial infarction, unstable angina, coronary artery bypass grafting, coronary angioplasty or stenting) or symptomatic pericarditis within 12 months prior to screening.
    2. History of documented congestive heart failure (New York Heart Association functional classification III-IV).
    3. Documented cardiomyopathy.
    4. Patient has a Left Ventricular Ejection Fraction (LVEF) <50% as determined by Multiple Gated acquisition (MUGA) scan or echocardiogram (ECHO).
    5. Clinically significant cardiac arrhythmias (e.g., ventricular tachycardia), complete left bundle branch block, high-grade AV block (e.g. bifascicular block, Mobitz type II and third-degree AV block).
    6. Long QT Syndrome or family history of idiopathic sudden death or congenital long QT syndrome or any of the following:
    7. Risk factors for Torsades de Pointe (TdP) including uncorrected hypokalemia or hypomagnesemia, history of cardiac failure or history of clinically significant/symptomatic bradycardia.
    8. QTc >500 msec or conduction abnormality in the previous 12 months.
    9. On screening 12-lead ECG, any of the following cardiac parameters: bradycardia (resting heart rate <50), tachycardia (resting heart rate >90), or QTcF interval ≥450 msec (using Fridericia's correction).
    10. Uncontrolled hypertension (Systolic blood pressure >160 mmHg or <90 mmHg and/or diastolic >100 mmHg).
11. Active infection requiring intravenous (IV) antibiotics.
12. Prior story of pneumonitis of any cause.
13. Prior thromboembolic events not attributable to a clear trigger cause.
14. Known human immunodeficiency virus (HIV) infection.
15. Any other diseases, active or uncontrolled pulmonary dysfunction, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug, that may compromise compliance with the protocol, that may affect the interpretation of the results, or renders the patients at high risk from treatment complications.
16. Significant traumatic injury within 3 weeks prior to initiation of study treatment.
17. Major surgical procedure (not including minor procedures such as lymph node biopsy, tumor core biopsy, fine needle aspiration or bilateral oophorectomy) within 3 weeks prior to initiation of study treatment or not fully recovered from any side effects of previous procedures.
18. Any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.

19. Patients with a history of any malignancy are ineligible except for the following circumstances:

    • Patients with a malignancy history other than invasive breast cancer are eligible if they have been disease-free for at least 5 years and are deemed by the investigator to be at low risk for recurrence of that malignancy.
    • Patients with the following cancers are eligible, even if diagnosed and treated within the past 5 years: ductal carcinoma in situ of the breast, cervical cancer in situ, and non-metastatic non-melanomatous skin cancers.
20. Estrogen replacement therapy stopped less than 2 weeks before treatment start.
21. Known hypersensitivity to any of the excipients of ribociclib, letrozole, goserelin or decapapetyl (if men or pre-menopausal).
22. Live vaccines within 30 days prior to the first dose of study.

23. Patients currently on following medications, which cannot be interrupted 7 days prior treatment start:

    1. Any prohibited medication as per goserelin or decapapetyl (pre-menopasual patients), letrozole or ribociclib label
    2. Herbal preparations/medications, dietary supplements.
    3. Medications that have a known risk to prolong the QT interval or cause Torsades de Pointe.
    4. Medications with a narrow therapeutic window and predominantly metabolized through CYP3A4.
    5. Strong inhibitors of CYP3A4, including grapefruit, grapefruit hybrids, pummelos, star-fruit and Seville oranges.
    6. Strong inducers of CYP3A4.
    7. Warfarin or other coumarin-derived anticoagulant for treatment, prophylaxis or otherwise. Therapy with heparin, low molecular weight heparin or fondaparinux is allowed.

24. A WOCBP who has a positive urine pregnancy test within 72 hours prior to allocation (see Appendix 1). If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.

    Note: in the event that 72 hours have elapsed between the screening pregnancy test and the first dose of study treatment, another pregnancy test (urine or serum) must be performed and must be negative in order for subject to start receiving study medication.

25. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
26. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
27. Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of trial treatment. Males who want to father children should consider preserving the sperm before starting treatment with ribociclib.
28. Persons deprived of their liberty or under protective custody or guardianship.

Contacts and Locations

Contacts

Contact: Fernando Salvador, PhD; +34 616 34 30 96; fernando.salvador@gruposolti.org

Contact: Ana Bargues; + 34 660 125 454; ana.bargues@gruposolti.org

Locations

France

Sainte Catherine - Institut du Cancer Avignon Provence; Recruiting

Avignon, France

Contact: Julien GRENIER

Centre Hospitalier de la Côte Basque; Recruiting

Bayonne, France

Contact: Thomas Grellety

Centre Hospitalier Universitaire de Besancon; Recruiting

Besançon, France

Contact: Laura MANSI

Hôpital Simone veil de Blois; Recruiting

Blois, France

Contact: Olivier ARSENE

Centre François Baclesse; Recruiting

Caen, France

Contact: George EMILE

Centre Hospitalier de Cholet; Recruiting

Cholet, France

Contact: Victor SIMMET

Centre Jean Perrin; Recruiting

Clermont-Ferrand, France

Contact: Marie-Ange OURET-REYNIER

Centre Georges François Leclerc; Recruiting

Dijon, France

Contact: Sylvain Ladoire

Centre Hospitalier Universitaire de Grenoble Alpes; Recruiting

Grenoble, France

Contact: Emmanuelle JACQUET

Hôpital Franco Britanique Fondation Cognacq Jay; Recruiting

Levallois-Perret, France

Contact: Nathalie PEREZ STAUB

Centre Oscar lambret; Recruiting

Lille, France

Contact: Audrey MAILLIEZ

Centre Hospitalier Universitaire de Limoges; Recruiting

Limoges, France

Contact: Elise DELUCHE

Centre Léon Berard; Recruiting

Lyon, France

Contact: Thomas BACHELOT

Hôpital privé Jean Mermoz; Recruiting

Lyon, France

Contact: Olfa DERBEL

Institut Paoli Calmettes; Recruiting

Marseille, France

Contact: Frederic VIRET

Hôpital privé de Confluent; Recruiting

Nantes, France

Contact: Dorothée CHOCTEAU-BOUJU

Institut Curie; Recruiting

Paris, France

Contact: Paul Cottu

Centre Hospitalier Universitaire de Poitiers; Recruiting

Poitiers, France

Contact: Nicolas ISAMBERT

Centre Hospitalier les Cornouaille; Recruiting

Quimper, France

Contact: Léa Muzellec

Institut Jean Godinot; Recruiting

Reims, France

Contact: Amélie LEMOINE

Centre Eugène Marquis; Recruiting

Rennes, France

Contact: Thibault DE LA MOTTE ROUGE

Institut Curie; Recruiting

Saint-Cloud, France

Contact: Paul Cottu

Centre Hospitalier Privé Saint-Grégoire; Recruiting

Saint-Grégoire, France

Contact: Romuald LE SCODAN

Clinique Mutualiste de l'Estuaire - Groupe HGO; Recruiting

Saint-Nazaire, France

Contact: Valérie DELECROIX

Clinique Sainte Anne - Strasbourg Oncologie Libérale; Recruiting

Strasbourg, France

Contact: Youssef TAZI

Institut de cancérologie Strasbourg Europe - ICANS; Recruiting

Strasbourg, France

Contact: Thierry PETIT

Hopitaux du Léman; Recruiting

Thonon-les-Bains, France

Contact: Francesco DEL PIANO

Clinique Pasteur; Recruiting

Toulouse, France

Contact: Chantal BERNARD-MARTY

Institut Claudius Regaud, IUCT-Oncopole; Recruiting

Toulouse, France

Contact: Florence DALENC

Nouvelle Clinique des Dentellières; Recruiting

Valenciennes, France

Contact: Géraldine LAURIDANT

Institut de Cancérologie de Lorraine; Recruiting

Vandœuvre-lès-Nancy, France

Contact: Maria RIOS

Centre Hospitalier Bretagne Atlantique; Recruiting

Vannes, France

Contact: Camille POIRIER

Gustave Roussy; Recruiting

Villejuif, France

Contact: Barbara PISTILLI

Portugal

Hospital da Luz; Suspended

Lisbon, Portugal

Hospital de São Francisco Xavier; Suspended

Lisbon, Portugal

IPO Porto; Suspended

Porto, Portugal

Spain

ICO Badalona; Recruiting

Badalona, Barcelona, Spain

Contact: Eudald Felip, 'MD

ICO Hospitalet; Recruiting

Hospitalet de Llobregat, Barcelona, Spain

Contact: Sonia Pernas, MD

Hospital Son Espases; Recruiting

Palma De Mallorca, Islas Baleares, Spain

Contact: Antonia Perelló, MD

Hospital Clinic de Barcelona; Recruiting

Barcelona, Spain

Contact: Maria Vidal, MD

Hospital Vall d'Hebron; Recruiting

Barcelona, Spain

Contact: Meritxell Bellet, MD

Hospital Universiatrio Clínico San Cecilio; Recruiting

Granada, Spain

Contact: Isabel Blancas, MD

Complejo Asistencial Universitario de León; Recruiting

León, Spain

Contact: Ana López González, MD

Fundación Jiménez Díaz; Recruiting

Madrid, Spain

Contact: Yann Izarzugaza

HM Sanchinarro; Recruiting

Madrid, Spain

Contact: Ana M Luna, MD

Hospital 12 de Octubre; Recruiting

Madrid, Spain

Contact: Eva M Ciruelos, MD

Hospital Ramón y Cajal; Recruiting

Madrid, Spain

Contact: Elena López, MD

Complejo Asistencial Universitario de Salamanca; Recruiting

Salamanca, Spain

Contact: Cesar Rodriguez, MD

Hospital Universitario Virgen del Rocío; Recruiting

Sevilla, Spain

Contact: Javier Salvador, MD

Hospital Clínico de Valencia; Recruiting

Valencia, Spain

Contact: Cristina Hernando, MD

Instituto Valenciano de Oncología; Recruiting

Valencia, Spain

Contact: Joaquín Gavilá, MD

Sponsors and Collaborators

SOLTI Breast Cancer Research Group

Novartis

UNICANCER

Investigators

• Principal Investigator: Aleix Prat, MD; Hospital Clínic de Barcelona/SOLTI
• Principal Investigator: Paul Cottu, MD; Institut Curie Paris
• Principal Investigator: Joaquín Gavilá, MD; Instituto Valenciano de Oncología
• Principal Investigator: Thibault de La Motte Rouge, MD; Centre Eugène Marquis, Rennes

More Information

• Responsible Party: SOLTI Breast Cancer Research Group
• ClinicalTrials.gov Identifier: NCT05296746
• Other Study ID Numbers: SOLTI-1911; BIG-21-02 ( Other Identifier: BIG )
• First Posted: March 25, 2022
• Last Update Posted: October 10, 2023
• Last Verified: October 2023

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by SOLTI Breast Cancer Research Group:

breast cancer; ribociclib; ROR score; chemotherapy

Additional relevant MeSH terms:

Breast Neoplasms; Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases